49 results about "IGFBP7" patented technology

The present invention provides diagnostic methods for predicting the effectiveness of treatment of an hepatocellular carcinoma (HCC) patient with an IGF-1R kinase inhibitor by assessing whether the HCC tumor cells express a high level of AFP, or whether serum levels of AFP protein are high. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-1R kinase inhibitors, based on a determination of the expression level of IR, IGF-2, IGFBP3 or IGFBP7 in tumor cells, or a 4-gene index calculated using the expression vales for each of these four genes, which can be used to identify tumors that will be sensitive to IGF-1R kinase inhibitors, and also those that will be insensitive. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methods are also provided.

The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.

Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.

The invention provides mutain of a human insulin-like growth factor conjugated protein 7 (IGFBP7). The mutain contains mutation of Arg198Ile/His200Phe, and has an amino acid sequence of SEQ ID NO.1. An igfbp7 gene coding sequence is selected from an SW480cDNA library of a human colorectal cancer cell line and is constructed into pET28a plasmids of a prokaryotic expression vector, so that the IGFBP7 protein can be expressed in a colon bacillus strain BL21. On the basis of the expression vector, mutain of the IGFBP7 is constructed, BL21 is converted, the mutain is expressed and purified, and a key site where the IGFBP7 is bonded with insulin is pointed out. The mutain provided by the invention has simple steps in a preparation method and high success rate, and the bonding capacity of the protein with insulin is remarkably reduced, so that insulin resistance can be suppressed and the mutain can be applied to the preparation of a medicament for treating type 2 diabetes.

The invention discloses a method and a kit for testing the carcass trait of a duck flock. The method for testing the carcass trait of the duck flock comprises: detecting haptotype, which is formed by SNP, of a duck IGFBP7 gene; and judging the haptotype gene of a duck sample to be tested and determining the carcass trait of the duck. The kit provided by the invention comprises PCR amplification primers for specifically amplifying the IGFBP7 gene and other PCR amplification agents. The method and the kit of the invention have simple and quick operation, and stable and reliable result. When used in assisted breeding screening, the method and the kit have the advantages of early screening, time conservation, low cost and high accuracy. The method and the kit have a promising application prospect in meat duck breeding practice.

The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.

The invention provides an application of a tumor inhibiting factor menin to diagnosis and treatment of pancreatic cancer. The mechanism that the menin factor inhibits growth of pancreatic cancer cells through overexpression is elaborated; on one hand, the menin factor inhibits growth of the pancreatic cancer cells by inhibiting expression of up-regulated genes p18, p27, HOXA9, HDAC5 and CBX4 and expression of down-regulated genes CDK2, CDK4, ESM1, IGFBP7 and GAS1; on the other hand, the menin factor is competitively combined with Dnmt1 to reduce the DNA methylation level of p18/p27 promoters and promotes transcription of p18/p27 genes to inhibit growth of the pancreatic cancer cells, and a new way is provided for treating the pancreatic cancer.

The invention belongs to the field of biological medicine, and mainly relates to application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis. The invention provides an application of a vascular secretion factor in preparation of a biomarker for detecting non-alcoholic steatohepatitis, and is characterized in that the vascular secretion factor comprises IGFBP7 and/or ADAMTS1; the IGFBP7 and/or the ADAMTS1 are/is expressed in an HDAC2 (histone deacetylase 2)/DNMT1-IGFBP7/ADAMTS1-Th17 signal channel. The invention also provides application of the vascular secretion factor in preparation of the biomarker for distinguishing the non-alcoholic steatohepatitis and the simple fatty liver, and is characterized in that the vascular secretion factor comprises IGFBP7 and/or ADAMTS1; the IGFBP7 and/or the ADAMTS1 are/is expressed in an HDAC2 (histone deacetylase 2)/DNMT1-IGFBP7/ADAMTS1-Th17 signal channel. The invention further provides application of the synergistic effect of the IGFBP7 and/or the ADAMTS1 in preparation of the biomarker for detecting the non-alcoholic steatohepatitis. According to the application provided by the invention, the non-alcoholic steatohepatitis can be evaluated more reliably, simply, conveniently and noninvasively.